These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9266421)

  • 21. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
    Ossege LM; Sindern E; Patzold T; Malin JP
    Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
    Guillemin GJ; Kerr SJ; Pemberton LA; Smith DG; Smythe GA; Armati PJ; Brew BJ
    J Interferon Cytokine Res; 2001 Dec; 21(12):1097-101. PubMed ID: 11798468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b.
    Laske C; Oschmann P; Tofighi J; Kühne BS; Diehl H; Bregenzer T; Kraus J; Chatzimanolis N; Bauer R; Traupe H; Kaps M
    Eur Neurol; 2001; 46(4):210-4. PubMed ID: 11721129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 27. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
    Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
    Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The interferon-beta 1b clinical trial and its implications for other trials.
    Paty DW
    Ann Neurol; 1994; 36 Suppl():S113-4. PubMed ID: 8017869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis.
    Qu ZX; Dayal A; Jensen MA; Arnason BG
    Arch Neurol; 1998 Mar; 55(3):315-21. PubMed ID: 9520005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of interferon-beta as a therapy for multiple sclerosis.
    Markowitz C
    Expert Opin Emerg Drugs; 2004 Nov; 9(2):363-74. PubMed ID: 15571491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
    Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
    Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

  • 35. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
    Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
    Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes.
    Jimenez J; Jy W; Mauro LM; Horstman LL; Ahn ER; Ahn YS; Minagar A
    Mult Scler; 2005 Jun; 11(3):310-5. PubMed ID: 15957513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon beta for secondary progressive multiple sclerosis.
    La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
    Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
    J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
    Schwid SR; Goodman AD; Mattson DH
    Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.